open access

Vol 91, No 6 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-06-30
Get Citation

Circulating omentin-1 levels and inflammation in polycystic ovary syndrome

Grzegorz Franik, Marcin Sadlocha, Pawel Madej, Aleksander Owczarek, Violetta Skrzypulec-Plinta, Ryszard Plinta, Jerzy Chudek, Magdalena Olszanecka-Glinianowicz
DOI: 10.5603/GP.2020.0057
·
Pubmed: 32627151
·
Ginekol Pol 2020;91(6):308-312.

open access

Vol 91, No 6 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-06-30

Abstract

Objectives: The aim of the study was to analyze interrelation between plasma omentin-1 levels and nutritional status and
inflammation in PCOS.
Material and methods: A cross-sectional study involving 86 PCOS (47 obese) and 72 Non-PCOS women (41 obese) determined
anthropometric parameters and body composition. Serum glucose, insulin and omentin-1, TNF-α, sTNFRs, IL-6 and
sR-IL6 were measured in the fasting state.
Results: Plasma omentin-1 levels were significantly lower in the PCOS than in the Non-PCOS group and both corresponding
normal weight and obese subgroups. In three analyzed least-angle regression (LARS) models the lower plasma omentin-
1 levels was associated with PCOS occurrence, higher circulating TNF-α and lower IL-6 levels.
Conclusions: Suppressed omentin-1 levels in PCOS are characteristic for this disturbance and proinflammatory cytokines
are factors modifying secretion of this adipokine.

Abstract

Objectives: The aim of the study was to analyze interrelation between plasma omentin-1 levels and nutritional status and
inflammation in PCOS.
Material and methods: A cross-sectional study involving 86 PCOS (47 obese) and 72 Non-PCOS women (41 obese) determined
anthropometric parameters and body composition. Serum glucose, insulin and omentin-1, TNF-α, sTNFRs, IL-6 and
sR-IL6 were measured in the fasting state.
Results: Plasma omentin-1 levels were significantly lower in the PCOS than in the Non-PCOS group and both corresponding
normal weight and obese subgroups. In three analyzed least-angle regression (LARS) models the lower plasma omentin-
1 levels was associated with PCOS occurrence, higher circulating TNF-α and lower IL-6 levels.
Conclusions: Suppressed omentin-1 levels in PCOS are characteristic for this disturbance and proinflammatory cytokines
are factors modifying secretion of this adipokine.

Get Citation

Keywords

omentin-1; inflammation; nutritional status; PCOS

About this article
Title

Circulating omentin-1 levels and inflammation in polycystic ovary syndrome

Journal

Ginekologia Polska

Issue

Vol 91, No 6 (2020)

Pages

308-312

Published online

2020-06-30

DOI

10.5603/GP.2020.0057

Pubmed

32627151

Bibliographic record

Ginekol Pol 2020;91(6):308-312.

Keywords

omentin-1
inflammation
nutritional status
PCOS

Authors

Grzegorz Franik
Marcin Sadlocha
Pawel Madej
Aleksander Owczarek
Violetta Skrzypulec-Plinta
Ryszard Plinta
Jerzy Chudek
Magdalena Olszanecka-Glinianowicz

References (26)
  1. Schäffler A, Neumeier M, Herfarth H, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005; 1732(1-3): 96–102.
  2. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006; 290(6): E1253–E1261.
  3. Fain JN, Sacks HS, Buehrer B, et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond). 2008; 32(5): 810–815.
  4. Yamawaki H, Kuramoto J, Kameshima S, et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun. 2011; 408(2): 339–343.
  5. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007; 56(6): 1655–1661.
  6. Tan BK, Adya R, Farhatullah S, et al. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes. 2010; 59(12): 3023–3031.
  7. Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010; 7: 27.
  8. Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci. 2010; 28(9): 993–998.
  9. Choi JH, Rhee EJ, Kim KH, et al. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011; 165(5): 789–796.
  10. Akbarzadeh S, Ghasemi S, Kalantarhormozi M, et al. Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemic and lipidemic markers with incidence of PCOS in women with normal BMI. Gynecol Endocrinol. 2012; 28(7): 521–524.
  11. Orlik B, Madej P, Owczarek A, et al. Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014; 81(4): 529–535.
  12. Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, et al. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol. 2007; 133(2): 197–202.
  13. Mahde A, Shaker M, Al-Mashhadani Z. Study of Omentin1 and Other Adipokines and Hormones in PCOS Patients. Oman Med J. 2009; 24(2): 108–118.
  14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  15. Olszanecka-Glinianowicz M, Madej P, Wdowczyk M, et al. Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2015; 172(2): 173–179.
  16. Olszanecka-Glinianowicz M, Madej P, Nylec M, et al. Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances. Clin Endocrinol (Oxf). 2013; 79(2): 238–242.
  17. Olszanecka-Glinianowicz M, Madej P, Zdun D, et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2012; 162(1): 55–61.
  18. Olszanecka-Glinianowicz M, Kuglin D, Dąbkowska-Huć A, et al. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011; 154(1): 51–56.
  19. Talmor A, Dunphy B. Female obesity and infertility. Best Pract Res Clin Obstet Gynaecol. 2015; 29(4): 498–506.
  20. de Melo AS, Dias SV, Cavalli Rd, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015; 150(1): R11–R24.
  21. Zak-Golab A, Zahorska-Markiewicz B, Langfort J, et al. [Obesity as inflammatory disease]. Postepy Hig Med Dosw (Online). 2008; 62(4): 249–257.
  22. Spritzer PM, Lecke SB, Satler F, et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015; 149(5): R219–R227.
  23. Cai RC, Wei Li, DI JZ, et al. [Expression of omentin in adipose tissues in obese and type 2 diabetic patients]. Zhonghua Yi Xue Za Zhi. 2009; 89(6): 381–384.
  24. Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, et al. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol. 2007; 133(2): 197–202.
  25. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Kocełak P, et al. The effect of weight loss on inflammation in obese women with polycystic ovary syndrome. Endokrynol Pol. 2008; 59(1): 13–17.
  26. Watanabe T, Watanabe-Kominato K, Takahashi Y, et al. Adipose Tissue-Derived Omentin-1 Function and Regulation. Compr Physiol. 2017; 7(3): 765–781.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl